Cart
sales@molnova.com
Tiotropium Bromide hydrate
CAS No. 139404-48-1
Tiotropium Bromide hydrate( BA-679 BR hydrate )
Catalog No. M17275 CAS No. 139404-48-1
Tiotropium Bromide hydrate is a monohydrate of tiotropium bromide (Spiriva; Tiova; BA 679BR; tiopropium) that is an anticholinergic and bronchodilator and a muscarinic receptor antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 59 | Get Quote |
|
| 10MG | 78 | Get Quote |
|
| 25MG | 141 | Get Quote |
|
| 50MG | 176 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTiotropium Bromide hydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionTiotropium Bromide hydrate is a monohydrate of tiotropium bromide (Spiriva; Tiova; BA 679BR; tiopropium) that is an anticholinergic and bronchodilator and a muscarinic receptor antagonist.
-
DescriptionTiotropium Bromide hydrate is a monohydrate of tiotropium bromide (Spiriva; Tiova; BA 679BR; tiopropium) that is an anticholinergic and bronchodilator and a muscarinic receptor antagonist.
-
In Vitro——
-
In Vivo——
-
SynonymsBA-679 BR hydrate
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorAChR
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number139404-48-1
-
Formula Weight490.43
-
Molecular FormulaC19H22NO4S2·Br·xH2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO.[Br-].[H][C@]12C[C@@H](C[C@]([H])([C@H]3O[C@@H]13)[N+]2(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Barnes PJ, et al. Life Sci, 1995, 56(11-12), 853-859.
molnova catalog
related products
-
Rezivertinib
Rezivertinib (BPI-7711) is an orally available, selective and potent inhibitor of tyrosine kinase (EGFR) with antitumor activity for central nervous system disorders.
-
DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.
-
Panitumumab
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
